At the Society of Hematological Oncology 2025 Annual Meeting, CancerNetwork® spoke with Sundar Jagannath, MBBS, about his presentation on potentially...

Tarlatamab-dlle (Imdelltra) plus an anti-PD-1 therapy retained long-term durability in the first-line for patients with extensive-stage small cell lun...

Recent data presented at a major oncology conference examined the clinical utility of circulating tumor DNA (ctDNA) monitoring combined with standard...

Generally, the communication in academic oncology institutions is favorable; however, when oncologists and pathologists become busy, specimens may be...

The pooled analysis explored outcomes for colorectal cancer patients who were circulating tumor DNA (ctDNA)–ctDNA-positive after surgery, achieved tra...

Results from the phase 3 ACROSS 2 trial (NCT04500717) revealed that aumolertinib plus chemotherapy significantly improved progression-free survival (P...

The ProSense® cryoablation system achieved the highest complete ablation rate compared with alternatives, with 95% of patients with breast cancer bein...

The combination of the MAT2A inhibitor IDE397 and sacituzumab govitrecan-hziy (Trodelvy) displayed promising activity in a small cohort of patients wi...

At the IASLC 2025 World Conference on Lung Cancer (WCLC), results from the phase 3 ALCHEMIST study (NCT02194738) were presented, showing that adjuvant...

The FDA has approved gemcitabine intravesical system (Inlexzo) for patients who have Bacillus Calmette-Guérin-unresponsive, non-muscle-invasive bladde...